Per-name detailThe 10 companies, in depth
1. ADBE Adobe Inc.
DEBATED
Software - Application · adj close 212.17 (div-adj)
Quality
97.4% pctile
Market doubt
1.00 / 1.00
News read — a real but unresolved debate — no clear damage yet: Stock down 38% on strategic shift (slowing growth metric). Real but unresolved secular question about Adobe's strategy.. Leaves the opportunity score about unchanged.
Business quality fingerprint
Returns
ROIC36.7% ▲
ROE61.3%
Gross profitability71.4% ▲
Margins
Gross margin88.6% –
Operating margin36.6% –
FCF margin41.4% (FCF+)
Growth (3-yr)
Revenue CAGR10.5%
EPS CAGR18.2%
Balance sheet
Net debt / EBITDA0.12
Share count (5-yr)-11.2%
Quality score0.88 · 97.4% pctile
What it does
Adobe Inc. stands as a prominent global software provider, delivering a diverse range of solutions. Its operations are structured into three primary business divisions: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment empowers individuals, teams, and enterprises to generate, disseminate, and amplify various forms of content through its array of products and services, including the cloud-native Document Cloud platform.
Doubt & mispricing
The market doubts it (score 1.00): trading cheap versus its own multi-year range; down 43% from its 1-year high, below its 200-day line. Early signs of a turn in margins or returns.
Recommended next step
HOLD OFF — CONFIRM THE TURN
The ROIC/margin upturn is only a period or two old. Wait for the next earnings report to confirm it's a trend (not one print), and watch for upward analyst estimate revisions before acting.
Notable: management is buying back stock into the weakness (shrinking share count) — a tentative confidence signal.
Recent news
2. LULU Lululemon Athletica Inc.
DOUBT = SENTIMENT
Apparel - Retail · adj close 110.63 (div-adj)
Quality
87.2% pctile
Market doubt
1.00 / 1.00
News read — the doubt looks like sentiment, not damage: Price decline amid broad market weakness; institutional buying signals; no fundamental damage reported.. Lifts the opportunity score to 0.96 (from 0.87).
Business quality fingerprint
Returns
ROIC22.7% ▼
ROE31.8%
Gross profitability74.3% ▲
Margins
Gross margin56.6% ▼
Operating margin19.9% ▼
FCF margin8.3% (FCF+)
Growth (3-yr)
Revenue CAGR11.0%
EPS CAGR25.7%
Balance sheet
Net debt / EBITDA-0.00
Share count (5-yr)-8.6%
Quality score0.76 · 87.2% pctile
What it does
Lululemon Athletica Inc., alongside its subsidiaries, specializes in the design, global distribution, and retail of athletic apparel and accessories for both women and men. Its business operations are structured into two main divisions: company-owned retail establishments and direct-to-consumer sales. The firm's offerings encompass a range of clothing such as pants, shorts, tops, and jackets, all crafted for promoting a healthy lifestyle and facilitating athletic endeavors. These activities span yoga, running, training, and other physically demanding pursuits.
Doubt & mispricing
The market doubts it (score 1.00): trading cheap versus its own multi-year range; down 51% from its 1-year high, below its 200-day line.
Recommended next step
BUY CANDIDATE — WORTH A CLOSE LOOK
Quality looks intact and cash-generative while the market is clearly doubting it — the doubt reads as price/sentiment more than broken fundamentals. Reasonable to start a small position and add on confirmation; first verify there's no company-specific bad news behind -50.6% (skim recent headlines + the last earnings call).
Notable: management is buying back stock into the weakness (shrinking share count) — a tentative confidence signal.
Recent news
3. ADSK Autodesk, Inc.
NEWS CONSTRUCTIVE
Software - Application · adj close 205.26 (div-adj)
Quality
87.4% pctile
Market doubt
0.85 / 1.00
News read — the news is constructive: Guggenheim Buy initiation with $245 target citing FY27 revenue upside and AI moat; institutional buying.. Lifts the opportunity score to 0.94 (from 0.74).
Business quality fingerprint
Returns
ROIC18.7% ▲
ROE36.9%
Gross profitability52.6% ▲
Margins
Gross margin91.0% ▲
Operating margin24.9% ▲
FCF margin33.4% (FCF+)
Growth (3-yr)
Revenue CAGR12.9%
EPS CAGR11.4%
Balance sheet
Net debt / EBITDA0.27
Share count (5-yr)-3.2%
Quality score0.76 · 87.4% pctile
What it does
Autodesk, Inc. delivers advanced software and services for 3D design, engineering, and entertainment to a global clientele. Their diverse product line includes AutoCAD Civil 3D, a comprehensive solution for civil engineering tasks such as land development, transportation infrastructure, and environmental projects. For construction project management, they offer BIM 360, a cloud-based platform.
Doubt & mispricing
The market doubts it (score 0.85): trading cheap versus its own multi-year range; down 37% from its 1-year high, below its 200-day line.
Recommended next step
BUY CANDIDATE — WORTH A CLOSE LOOK
Quality looks intact and cash-generative while the market is clearly doubting it — the doubt reads as price/sentiment more than broken fundamentals. Reasonable to start a small position and add on confirmation; first verify there's no company-specific bad news behind -37.2% (skim recent headlines + the last earnings call).
Notable: management is buying back stock into the weakness (shrinking share count) — a tentative confidence signal.
Recent news
4. CPRT Copart, Inc.
DOUBT = SENTIMENT
Specialty Business Services · adj close 27.20 (div-adj)
Quality
90.8% pctile
Market doubt
0.94 / 1.00
News read — the doubt looks like sentiment, not damage: Price decline amid market volatility; no fundamental damage, earnings miss, guidance cut, or hard negatives reported.. Lifts the opportunity score to 0.90 (from 0.85).
Business quality fingerprint
Returns
ROIC14.7% ▼
ROE16.9%
Gross profitability20.8% ▼
Margins
Gross margin45.2% ▼
Operating margin36.5% ▼
FCF margin26.5% (FCF+)
Growth (3-yr)
Revenue CAGR9.9%
EPS CAGR12.1%
Balance sheet
Net debt / EBITDA-1.27
Share count (5-yr)+1.7%
Quality score0.79 · 90.8% pctile
What it does
Copart, Inc. stands as a prominent global provider of online vehicle auctions and comprehensive vehicle remarketing services. The company extends its operations across numerous international markets, including the United States, the United Kingdom, Germany, Brazil, Canada, the United Arab Emirates, Spain, Finland, Oman, the Republic of Ireland, and Bahrain. At its core, Copart enables the buying and selling of vehicles over the internet through its sophisticated "virtual bidding" online auction platform.
Doubt & mispricing
The market doubts it (score 0.94): trading cheap versus its own multi-year range; down 46% from its 1-year high, below its 200-day line.
Recommended next step
BUY CANDIDATE — WORTH A CLOSE LOOK
Quality looks intact and cash-generative while the market is clearly doubting it — the doubt reads as price/sentiment more than broken fundamentals. Reasonable to start a small position and add on confirmation; first verify there's no company-specific bad news behind -45.6% (skim recent headlines + the last earnings call).
Notable: the balance sheet holds net cash, which de-risks the wait.
Recent news
5. ISRG Intuitive Surgical, Inc.
DOUBT = SENTIMENT
Medical - Devices · adj close 332.02 (div-adj)
Quality
91.2% pctile
Market doubt
0.96 / 1.00
News read — the doubt looks like sentiment, not damage: Post-earnings pullback despite strong results; valuation-driven selloff with no fundamental deterioration.. Lifts the opportunity score to 0.90 (from 0.88).
Business quality fingerprint
Returns
ROIC13.7% –
ROE16.0%
Gross profitability32.2% ▲
Margins
Gross margin66.0% ▼
Operating margin29.3% ▼
FCF margin24.7% (FCF+)
Growth (3-yr)
Revenue CAGR17.4%
EPS CAGR29.2%
Balance sheet
Net debt / EBITDA-0.77
Share count (5-yr)-0.8%
Quality score0.80 · 91.2% pctile
What it does
Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care by developing, producing, and commercializing sophisticated tools. These innovations empower medical professionals to deliver superior, accessible, and less-invasive treatment options to patients both within the United States and across international markets. Its flagship offering, the da Vinci Surgical System, facilitates intricate operations through a minimally disruptive approach.
Doubt & mispricing
The market doubts it (score 0.96): trading cheap versus its own multi-year range; down 44% from its 1-year high, below its 200-day line.
Recommended next step
BUY CANDIDATE — WORTH A CLOSE LOOK
Quality looks intact and cash-generative while the market is clearly doubting it — the doubt reads as price/sentiment more than broken fundamentals. Reasonable to start a small position and add on confirmation; first verify there's no company-specific bad news behind -44.0% (skim recent headlines + the last earnings call).
Notable: the balance sheet holds net cash, which de-risks the wait.
Recent news
6. ZTS Zoetis Inc.
DOUBT EARNED
Drug Manufacturers - General · adj close 74.57 (div-adj)
Quality
92.8% pctile
Market doubt
1.00 / 1.00
News read — the doubt looks earned: Securities class action lawsuit filed against Zoetis shareholders; hard negative catalyst per decision rule #1.. Cuts the opportunity score to 0.88 (from 0.93).
Business quality fingerprint
Returns
ROIC21.5% ▲
ROE80.2%
Gross profitability43.1% ▲
Margins
Gross margin70.5% ▲
Operating margin38.0% ▲
FCF margin24.1% (FCF+)
Growth (3-yr)
Revenue CAGR5.4%
EPS CAGR10.3%
Balance sheet
Net debt / EBITDA1.76
Share count (5-yr)-6.9%
Quality score0.81 · 92.8% pctile
What it does
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents.
Doubt & mispricing
The market doubts it (score 1.00): trading cheap versus its own multi-year range; down 52% from its 1-year high, below its 200-day line.
Recommended next step
RECONSIDER — DOUBT MAY BE EARNED
Quality looks intact and cash-generative while the market is clearly doubting it — the doubt reads as price/sentiment more than broken fundamentals. Reasonable to start a small position and add on confirmation; first verify there's no company-specific bad news behind -51.9% (skim recent headlines + the last earnings call).
Recent news points to realized deterioration, not just sentiment — the cheapness may be a value trap. Confirm the cause before acting (base read would say ‘Buy Candidate’).
Notable: management is buying back stock into the weakness (shrinking share count) — a tentative confidence signal.
Recent news
7. IT Gartner, Inc.
DOUBT = SENTIMENT
Consulting Services · adj close 133.69 (div-adj)
Quality
84.4% pctile
Market doubt
0.99 / 1.00
News read — the doubt looks like sentiment, not damage: Single-day 4.5% underperformance vs. broad market on favorable session; no fundamental catalyst or analyst signal.. Lifts the opportunity score to 0.87 (from 0.83).
Business quality fingerprint
Returns
ROIC18.8% ▲
ROE227.9%
Gross profitability54.4% ▲
Margins
Gross margin67.7% ▼
Operating margin15.8% ▼
FCF margin18.1% (FCF+)
Growth (3-yr)
Revenue CAGR5.9%
EPS CAGR-1.0%
Balance sheet
Net debt / EBITDA1.54
Share count (5-yr)-16.3%
Quality score0.73 · 84.4% pctile
What it does
Gartner, Inc. functions as a premier research and advisory enterprise, extending its reach across the United States, Canada, Europe, the Middle East, Africa, and various international markets. Its operations are structured into three main divisions: Research, Conferences, and Consulting. The Research division primarily offers a subscription service, enabling on-demand access to extensive published studies, data, industry benchmarks, and direct consultations with its expert network.
Doubt & mispricing
The market doubts it (score 0.99): trading cheap versus its own multi-year range; down 63% from its 1-year high, below its 200-day line.
Recommended next step
BUY CANDIDATE — WORTH A CLOSE LOOK
Quality looks intact and cash-generative while the market is clearly doubting it — the doubt reads as price/sentiment more than broken fundamentals. Reasonable to start a small position and add on confirmation; first verify there's no company-specific bad news behind -62.7% (skim recent headlines + the last earnings call).
Notable: management is buying back stock into the weakness (shrinking share count) — a tentative confidence signal.
Recent news
8. NFLX Netflix, Inc.
DOUBT = SENTIMENT
Entertainment · adj close 68.89 (div-adj)
Quality
95.4% pctile
Market doubt
0.89 / 1.00
News read — the doubt looks like sentiment, not damage: Price pullback with no hard negatives mentioned; headlines frame as buying opportunity, not fundamental damage.. Lifts the opportunity score to 0.87 (from 0.85).
Business quality fingerprint
Returns
ROIC25.2% ▲
ROE41.3%
Gross profitability39.4% ▲
Margins
Gross margin48.5% ▲
Operating margin29.5% ▲
FCF margin20.9% (FCF+)
Growth (3-yr)
Revenue CAGR12.6%
EPS CAGR36.3%
Balance sheet
Net debt / EBITDA0.18
Share count (5-yr)-5.2%
Quality score0.84 · 95.4% pctile
What it does
Netflix, Inc. serves as a worldwide entertainment provider. Its comprehensive library features television series, motion pictures, documentaries, and mobile games, spanning numerous genres and languages. Members can effortlessly stream this content through a variety of internet-connected devices, including smart TVs, digital media players, cable boxes, and mobile phones.
Doubt & mispricing
The market doubts it (score 0.89): trading cheap versus its own multi-year range; down 45% from its 1-year high, below its 200-day line.
Recommended next step
BUY CANDIDATE — WORTH A CLOSE LOOK
Quality looks intact and cash-generative while the market is clearly doubting it — the doubt reads as price/sentiment more than broken fundamentals. Reasonable to start a small position and add on confirmation; first verify there's no company-specific bad news behind -45.5% (skim recent headlines + the last earnings call).
Notable: management is buying back stock into the weakness (shrinking share count) — a tentative confidence signal.
Recent news
9. IDXX IDEXX Laboratories, Inc.
DOUBT = SENTIMENT
Medical - Diagnostics & Research · adj close 539.37 (div-adj)
Quality
98.2% pctile
Market doubt
0.81 / 1.00
News read — the doubt looks like sentiment, not damage: Pure valuation pullback; no hard negatives, analyst consensus bullish (9/15 buy), no guidance cuts or demand signals.. Lifts the opportunity score to 0.84 (from 0.80).
Business quality fingerprint
Returns
ROIC40.3% ▼
ROE66.0%
Gross profitability79.4% ▲
Margins
Gross margin61.8% ▲
Operating margin31.6% ▲
FCF margin24.5% (FCF+)
Growth (3-yr)
Revenue CAGR8.5%
EPS CAGR17.7%
Balance sheet
Net debt / EBITDA0.61
Share count (5-yr)-6.8%
Quality score0.89 · 98.2% pctile
What it does
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments.
Doubt & mispricing
The market doubts it (score 0.81): trading cheap versus its own multi-year range; down 30% from its 1-year high, below its 200-day line. Early signs of a turn in margins or returns.
Recommended next step
HOLD OFF — CONFIRM THE TURN
The ROIC/margin upturn is only a period or two old. Wait for the next earnings report to confirm it's a trend (not one print), and watch for upward analyst estimate revisions before acting.
Notable: management is buying back stock into the weakness (shrinking share count) — a tentative confidence signal.
Recent news
10. RMD ResMed Inc.
DOUBT = SENTIMENT
Medical - Devices · adj close 191.89 (div-adj)
Quality
97.2% pctile
Market doubt
0.82 / 1.00
News read — the doubt looks like sentiment, not damage: Stock down 30% from peak despite record FCF of $1.7B and revenue growth. No hard negatives, analyst downgrades, or fundamental deterioration evident.. Lifts the opportunity score to 0.84 (from 0.80).
Business quality fingerprint
Returns
ROIC19.6% ▲
ROE23.5%
Gross profitability37.4% ▼
Margins
Gross margin59.4% ▲
Operating margin32.7% ▲
FCF margin32.3% (FCF+)
Growth (3-yr)
Revenue CAGR12.9%
EPS CAGR21.5%
Balance sheet
Net debt / EBITDA-0.19
Share count (5-yr)+0.6%
Quality score0.88 · 97.2% pctile
What it does
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices.
Doubt & mispricing
The market doubts it (score 0.82): trading cheap versus its own multi-year range; down 34% from its 1-year high, below its 200-day line.
Recommended next step
BUY CANDIDATE — WORTH A CLOSE LOOK
Quality looks intact and cash-generative while the market is clearly doubting it — the doubt reads as price/sentiment more than broken fundamentals. Reasonable to start a small position and add on confirmation; first verify there's no company-specific bad news behind -34.2% (skim recent headlines + the last earnings call).
Notable: the balance sheet holds net cash, which de-risks the wait.
Recent news